Tech Company Financing Transactions
Nuvalent Funding Round
Nuvalent, operating out of Cambridge, secured $135 million in funding from Bain Capital Life Sciences, Avoro Capital Advisors and Boxer Capital.
Transaction Overview
Company Name
Announced On
5/12/2021
Transaction Type
Venture Equity
Amount
$135,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds for the clinical advancement of its parallel lead programs, NVL-520 (previously NUV-520), a potential best-in-class ROS1-selective kinase inhibitor, and NVL-655 (previously NUV-655), a potential best-in-class ALK-selective kinase inhibitor, and further expansion and accelerated development of its discovery research pipeline of novel, selective small molecule kinase inhibitors.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1 Bdwy. 14th Floor
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
James Porter
Chief Financial Officer
Alex Balcom
Chief Medical Officer
Christopher Turner
Vice President
Benjamin Lane
Vice President
Henry Pelish
Vice President
John Soglia
VP - Operations
Ruth Adams
VP - Regulatory Affairs
Darlene Noci
Browse more venture capital transactions:
Prev: 5/11/2021: CB Therapeutics venture capital transaction
Next: 5/12/2021: Mythic venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs